State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to ...
Synopsys SNPS shares plunged 20.8% over the past year, underperforming the Zacks Computer - Software industry, Zacks Computer ...
Synopsys (NASDAQ:SNPS – Free Report) had its price target decreased by Piper Sandler from $655.00 to $653.00 in a report released on Thursday,Benzinga reports. Piper Sandler currently has an ...
This post was written by Luke Carberry Mogan. SNPS' first-quarter performance is likely to have benefited from the rising adoption of EDA, IP solutions and Synopsys.ai platform. Get a deeper ...
Would you like to be notified of the latest news and updates on the stock market?
Synopsys SNPS delivered better-than-expected first-quarter fiscal 2025 results. The company reported non-GAAP earnings of $3.03 per share for the first quarter, surpassing the Zacks Consensus ...
Despite a dip in overall revenue, Synopsys Inc (SNPS) sees growth in Design Automation and advances in AI-driven solutions.
A comprehensive national study examining dementia patient outcomes for Medicare Advantage beneficiaries with Alzheimer's disease and related dementias (ADRD) uncovered key insights into healthcare ...
Loop Capital Markets analyst Gary Mobley reiterated a Buy rating on Synopsys (SNPS – Research Report) today and set a price target of $650.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback